Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2020 Sep 29;29(12):2608–2616. doi: 10.1158/1055-9965.EPI-20-0659

Table 3.

Physical Activity and Symptom Descriptives

Variable Unadjusted Means (SD) p-value Unadjusted Means (SD) p-value
Overall Model 1 Model 2 T1 (a) T2 (b) T3 (c) Model 1 Model 2
Daily Symptom
Affect 2.88 (2.09) 2.71 (2.08)c 2.95(2.09) 3.01 (2.10)a 0.03 0.01
Pre-CT Dose 2.01(1.90) <0.001 <0.001 1.83( (1.96) 1.95 (1.81) 2.31 (1.88) 0.34 0.13
Day-of/Post-CT Dose 3.24 (2.07) 3.09 (2.01) 3.35 (2.06) 3.31 (2.12)
Anxiety 1.88 (0.94) 1.96(0.98) 1.84 (0.92) 1.93 (0.95) 0.63 <0.01
Pre-CT Dose 1.79 (0.88) <0.01 0.03 1.90 (0.93) 1.64 (0.77) 1.84 (0.92) 0.01 0.05
Day-of/Post-CT Dose 1.91 (0.96) 1.98 (1.00) 1.78 (0.90) 1.97 (0.96)
Depression 1.43 (0.61) 1.43 (0.61) 1.40 (0.59) 1.44 (0.63) 0.77 <0.001
Pre-CT Dose 1.35 (0.56) <0.001 <0.001 1.31 (0.52) 1.35 (0.55) 1.40 (0.62) <0.01 0.01
Day-of/Post-CT Dose 1.46 (0.63) 1.48 (0.63) 1.43 (0.61) 1.46 (0.64)
Fatigue 2.15 (0.74) 2.09 (0.69)c 2.14 (0.73)c 2.21 (0.78)a,b 0.01 0.05
Pre-CT Dose 1.86 (0.66) <0.001 <0.001 1.76 (0.62) 1.86 (0.66) 2.00 (0.69) <0.001 0.04
Day-of/Post-CT Dose 2.26 (0.74) 2.23 (0.68) 2.26 (0.73) 2.30 (0.80)
Physical Function-ADL 1.74 (0.89) 1.64 (0.84)c 1.56 (0.81) 1.81 (0.94)a <0.001 <0.001
Pre-CT Dose 1.44 (0.70) <0.001 <0.001 1.33 (0.60) 1.46 (0.66) 1.56 (0.82) 0.91 0.40
Day-of/Post-CT Dose 1.86 (0.93) 1.77 (0.89) 1.90 (0.94) 1.92 (0.97)
Physical Function-Walk 1.73 (0.92) 1.57 (0.78)b,c 1.81 (1.00)a 1.81 (0.95)a <0.001 <0.001
Pre-CT Dose 1.39 (0.72) <0.001 <0.001 1.21 (0.47) 1.46 (0.81) 1.54 (0.80) 0.48 0.49
Day-of/Post-CT Dose 1.86 (0.96) 1.71 (0.83) 1.96 (1.03) 1.93 (0.98)
Pain 1.62 (2.05) 1.34 (1.84)c 1.71 (2.06)a 1.86 (2.24)a 0.02 0.23
Pre-CT Dose 1.19 (1.98) <0.001 <0.001 0.82 (1.61) 1.24 (1.95) 1.60 (2.31) 0.30 0.88
Day-of/Post-CT Dose 1.79 (2.06) 1.55 (1.88) 1.90 (2.08) 1.97 (2.21)
Cognitive Function 2.05 ((0.91) 2.02 (0.88) 2.03 (0.91) 2.11 (0.94) 0.35 0.73
Pre-CT Dose 1.89(0.89) <0.001 <0.001 1.81(0.85) 1.90 (0.93) 1.96 (0.89) 0.04 0.15
Day-of/Post-CT Dose 2.11 (0.91) 2.10 (0.89) 2.07 (0.90) 2.17 (0.95)
Daily Activity Intensities (mins)
MVPA 22.74 (27.57) 22.22 (21.87)c 22.39 (26.85) 23.78 (33.85)a 0.45 <0.001
Pre-CT Dose 26.28 (24.22) <0.01 <0.001 27.07 (23.68) 27.08 (25.89) 24.43 (22.89) 0.01 0.60
Day-of/Post-CT Dose 21.25 (28.73) 20.32 (2.39) 20.48 (27.00) 23.50 (37.51)
Light Physical Activity 228.44 (92.64) 226.66 (81.15)b,c 230.41 (99.45)a 228.36 (97.62)a <0.001 <0.001
Pre-CT Dose 238.41 (89.33) <0.01 <0.001 245.50 (83.04) 238.20 (96.36) 229.83 (88.19) <0.001 <0.001
Day-of/Post-CT Dose 224.24 (93.69) 218.48 (78.96) 227.25 (100.54) 227.74 (101.34)

Note: CT= Chemotherapy; Values in bold indicate significant group difference. Model 1 examined time point and treatment status independently except for the interaction model which included both time point and treatment status and the time point*treatment status interaction. Model 2 included time point, treatment status, time point*treatment status interaction and relevant covariates including age, BMI, number of comorbidities, health status, disease stage, type of chemotherapy (neoadjuvant v. adjuvant), weekend day, and treatment cycle number. All physical activity models controlled for wear time.

a,b,c

Comparison between time points where a= time point 1; b= time point 2; c=time point 3 and indicate significance between groups at p<0.017 when controlling for covariates, treatment status and time point*treatment status interaction.